Tuesday, March 22, 2011

InSite cataract surgery trial results could target market leader

A once-daily topical anti-inflammatory and anti-pain eye drug from InSite Vision Inc. was superior to a commercially available, higher-dose, twice-a-day version of essentially the same drug for patients undergoing cataract surgery, the company said after looking at early data from a Phase I/II study.
The four-arm, 169-patient study showed that ISV-303, a low-dose nonsteroidal anti-inflammatory drug that uses the active ingredient bromfenac, performed better than ISTA Pharmaceuticals’ Xibrom as well as a placebo, according to Alameda-based InSite.

1 comment:

  1. Nice scenario. It contain good info about market leader about cataract surgery. I would really appreciate it.
    rhinoplasty

    ReplyDelete